Want to see IKT full AI Analyst Report?

Inhibikase Therapeutics (IKT) Price & Analysis

381 Followers

IKT Stock Chart & Stats

$1.83

$0.06(1.71%)

At close: Jan 08 4:00 PM EST

$1.83

$0.06(1.71%)

Day’s Range― - ―

52-Week Range$1.33 - $2.53

Previous CloseN/A

Volume38.02K

Average Volume (3M)1.05M

Market Cap

$333.49M

Enterprise Value$195.36

Total Cash (Recent Filing)$159.02M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.66

Next Earnings

Nov 16, 2026

EPS Estimate

-0.11

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.48

Shares Outstanding139,535,900

10 Day Avg. Volume1,384,669

30 Day Avg. Volume1,052,622

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)1.17

Price to Sales (P/S)0.00

P/FCF Ratio-7.25

Enterprise Value/Market Cap<0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$6.40

Price Target Upside249.73% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-0.44

Revenue Forecast (FY)$300.00K

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetMinimal debt reduces interest burden and financial risk, giving Inhibikase greater flexibility to fund clinical development. Although equity has declined, the capital structure remains less leveraged than many development-stage biotechs.

Late-stage Clinical ProgressProgress across approvals and trial sites supports execution of the pivotal Phase 3 program. Continued enrollment and regulatory activity can improve the probability of generating decision-relevant data for IKT-001.

Extended Development RunwayAdditional funding reduces the immediate risk of a financing interruption before the key Phase 3 readout. This provides time to complete development activities and preserve strategic options while clinical evidence matures.

Bears Say

No Commercial Revenue ScaleThe absence of sustained revenue confirms that the company remains dependent on clinical success rather than an operating commercial franchise. Revenue visibility will remain limited until a candidate is approved and launched.

Widening Net LossesWidening losses increase the resources required to reach regulatory milestones and reduce earnings visibility. This pattern is consistent with development-stage biotech, but it leaves results highly dependent on future clinical and regulatory outcomes.

Persistent Cash Burn And Funding DependenceSustained negative operating and free cash flow means ongoing equity financing or other capital will likely be needed to support development. Future funding requirements can pressure shareholders and constrain strategic flexibility.

Inhibikase Therapeutics News

Inhibikase Therapeutics reports Q2 EPS (11c), consensus (9c)

“During our second quarter and in recent weeks we continued to advance our Phase 3 IMPROVE-PAH study with...

12d ago

IKT

Inhibikase Therapeutics Faces Rising BIOSECURE, China Supply Chain and Trial Risks That Could Disrupt Growth

Inhibikase Therapeutics, Inc. (IKT) has disclosed a new risk, in the Regulation category. Inhibikase Therapeutics, Inc. faces growing...

10d ago

IKT

Analyst Reiterates Buy on IKT, Maintaining $8 Price Target Amid Regulatory Progress and Phase 3 PAH Trial Momentum

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Inhibikase Therapeutics and keeping the price target...

23d ago

IKT

Inhibikase Therapeutics Executes Pre-Funded Warrant Exchange

The latest update is out from Inhibikase Therapeutics ( ($IKT) ). On July 29, 2026, Inhibikase Therapeutics entered...

25d ago

IKT

Inhibikase Gains FDA Orphan Drug Status for IKT-001

Inhibikase Therapeutics ( ($IKT) ) has issued an update. On July 23, 2026, Inhibikase Therapeutics announced that the...

1M ago

IKT

Inhibikase Therapeutics IKT-001 gets Orphan Drug Designation from FDA

Inhibikase Therapeutics (IKT) announced that the FDA has granted Orphan Drug Designation to its lead product candidate IKT-001,...

1M ago

IKT

Inhibikase Therapeutics’ treatment of PAH granted FDA orphan designation

Inhibikase Therapeutics (IKT)’ treatment of pulmonary arterial hypertension was granted FDA orphan designation, according to a post on...

1M ago

IKT

Inhibikase raises $50M to fund PAH program

Inhibikase Therapeutics ( ($IKT) ) just unveiled an update. On July 14, 2026, Inhibikase Therapeutics announced that it...

1M ago

IKT

Inhibikase Shareholders Approve Governance and Compensation Changes

Inhibikase Therapeutics ( ($IKT) ) has issued an announcement. At its annual meeting on June 26, 2026, Inhibikase...

2M ago

IKT

Inhibikase Therapeutics initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of Inhibikase Therapeutics (IKT) with an Outperform rating and $5 price target Inhibikase is developing...

2M ago

IKT

Inhibikase Therapeutics: Buy Rating Reiterated on Advancing Phase 3 PAH Program and Robust IP, Price Target Maintained at $8

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Inhibikase Therapeutics, with...

3M ago

IKT

Analyst Flags High Risk in Inhibikase Therapeutics Stock, Urges Investors to Review 2025 Form 10-K Risk Factors

Inhibikase Therapeutics, Inc. (IKT) has disclosed a new risk, in the Regulation category. An external analyst notes that...

3M ago

IKT

Inhibikase Advances IKT-001 Into Adaptive Phase 3 Trial for Pulmonary Arterial Hypertension

Inhibikase Therapeutics, Inc. ($IKT) announced an update on their ongoing clinical study. Inhibikase Therapeutics has launched a late-stage...

3M ago

IKT

Buy Rating on IKT-001: De-Risked Late-Stage PAH Program with Adaptive Phase 3 Design and Solid Financial Runway

Maxim Group analyst Jason McCarthy reiterated a Buy rating on Inhibikase Therapeutics yesterday and set a price target...

5M ago

IKT

IKT FAQ

What was Inhibikase Therapeutics, Inc.’s price range in the past 12 months?

Inhibikase Therapeutics, Inc. lowest stock price was $1.33 and its highest was $2.53 in the past 12 months.

What is Inhibikase Therapeutics, Inc.’s market cap?

Inhibikase Therapeutics, Inc.’s market cap is $333.49M.

When is Inhibikase Therapeutics, Inc.’s upcoming earnings report date?

Inhibikase Therapeutics, Inc.’s upcoming earnings report date is Nov 16, 2026 which is in 85 days.

How were Inhibikase Therapeutics, Inc.’s earnings last quarter?

Inhibikase Therapeutics, Inc. released its earnings results on Aug 11, 2026. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.108 by -$0.002.

Is Inhibikase Therapeutics, Inc. overvalued?

According to Wall Street analysts Inhibikase Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Inhibikase Therapeutics, Inc. pay dividends?

Inhibikase Therapeutics, Inc. does not currently pay dividends.

What is Inhibikase Therapeutics, Inc.’s EPS estimate?

Inhibikase Therapeutics, Inc.’s EPS estimate is -0.11.

How many shares outstanding does Inhibikase Therapeutics, Inc. have?

Inhibikase Therapeutics, Inc. has 139,535,900 shares outstanding.

What happened to Inhibikase Therapeutics, Inc.’s price movement after its last earnings report?

Inhibikase Therapeutics, Inc. reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.108. Following the earnings report the stock price went down -2.041%.

Which hedge fund is a major shareholder of Inhibikase Therapeutics, Inc.?

Currently, no hedge funds are holding shares in IKT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Inhibikase Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

84.11%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.

Inhibikase Therapeutics (IKT) Earnings & Revenues

Historic Earnings Reports

IKT Stock 12 Month Forecast

Average Price Target

$6.40

▲(249.73% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","9":"$9","2.25":"$2.25","4.5":"$4.5","6.75":"$6.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.25,4.5,6.75,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.18,2.6276923076923078,3.075384615384616,3.5230769230769234,3.970769230769231,4.418461538461539,4.866153846153846,5.313846153846154,5.761538461538462,6.2092307692307696,6.656923076923077,7.104615384615386,7.552307692307693,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.18,2.5046153846153847,2.8292307692307697,3.153846153846154,3.4784615384615387,3.8030769230769232,4.127692307692308,4.452307692307693,4.776923076923078,5.101538461538462,5.426153846153847,5.750769230769231,6.075384615384616,{"y":6.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.18,2.396923076923077,2.613846153846154,2.830769230769231,3.0476923076923077,3.264615384615385,3.4815384615384617,3.6984615384615385,3.9153846153846157,4.132307692307693,4.349230769230769,4.566153846153846,4.783076923076923,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.52,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.76,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.61,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.05,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.57,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.93,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.91,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.71,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.94,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.18,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >